DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note released on Saturday. The firm issued a hold rating on the stock.

Separately, JMP Securities restated a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Stock Down 5.5 %

NASDAQ DBVT opened at $4.99 on Friday. The stock has a market cap of $102.64 million, a PE ratio of -1.11 and a beta of 0.71. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $8.32. The business has a 50 day moving average price of $4.48 and a two-hundred day moving average price of $3.83.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent quarter. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.